Literature DB >> 10878552

Macrophage-derived MT1-MMP and increased MMP-2 activity are associated with glomerular damage in crescentic glomerulonephritis.

K Hayashi1, S Horikoshi, S Osada, K Shofuda, I Shirato, Y Tomino.   

Abstract

Membrane-type matrix metalloproteinases (MT-MMPs) have been shown to activate pro-MMP-2 on the cell surface and are suggested to be key enzymes in tissue remodelling under various physiological and pathological conditions. To investigate the role of MT-MMP in progressive renal injury, the gene expression and enzymatic activity of MT-MMP were examined in crescentic glomerulonephritis induced by anti-glomerular basement membrane (GBM) antibody in WKY rats. Isolated glomeruli were subjected to RNA and protein extraction 0, 1, 3, 7, 14, and 28 days after intravenous injection of rabbit anti-GBM antibody. Semiquantitative RT-PCR analysis revealed that among the three members of the MT-MMP family, mRNA expression of MT2-MMP remained unchanged and that of MT3-MMP was not observed in glomeruli during the development of nephritis. However, MT1-MMP gene expression increased from day 3 and reached maximum levels at day 7 (5.5+/-0.7-fold increase over day 0), closely associated with macrophage accumulation, crescent formation, and increased proteinuria. Gelatin zymography showed that the active from of MMP-2 emerged from day 7 and remained during the experimental period accompanied by increased proMMP-2, while no active form of MMP-2 was found in control rats. Using an antisense cRNA probe, intense signals of MT1-MMP mRNA were observed mostly in cells within the crescent and in some cells in the mesangial areas. Most of these cells were ED-1-positive macrophages, based on immunostaining of sequential sections. These results suggested that in the MT-MMP family, MT1-MMP was induced in infiltrating macrophages during the development of crescentic glomerulonephritis and possibly contributed to pathological degradation of glomerular extracellular matrices through the activation of proMMP-2. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878552     DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH637>3.0.CO;2-L

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

1.  Chronic humoral rejection of human kidney allografts is associated with MMP-2 accumulation in podocytes and its release in the urine.

Authors:  W Wong; J DeVito; H Nguyen; D Sarracino; F Porcheray; I Dargon; P D Pelle; A B Collins; N Tolkoff-Rubin; R N Smith; R Colvin; E Zorn
Journal:  Am J Transplant       Date:  2010-11       Impact factor: 8.086

2.  Co-operative interactions between NFAT (nuclear factor of activated T cells) c1 and the zinc finger transcription factors Sp1/Sp3 and Egr-1 regulate MT1-MMP (membrane type 1 matrix metalloproteinase) transcription by glomerular mesangial cells.

Authors:  Maria Alejandra Alfonso-Jaume; Rajeev Mahimkar; David H Lovett
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

3.  Egr-1 mediates Si0(2)-driven transcription of membrane type I matrix metalloproteinase in macrophages.

Authors:  Fei Xiang; Ming Bai; Yang Jin; Wanli Ma; Jianbao Xin
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-02

4.  Membrane-type 1 matrix metalloproteinase regulates macrophage-dependent elastolytic activity and aneurysm formation in vivo.

Authors:  Wanfen Xiong; Rebecca Knispel; Jason MacTaggart; Timothy C Greiner; Stephen J Weiss; B Timothy Baxter
Journal:  J Biol Chem       Date:  2008-11-14       Impact factor: 5.157

5.  Expression of matrix metalloproteinases in patients with Wegener's granulomatosis.

Authors:  V Bjerkeli; B Halvorsen; J K Damås; I Nordøy; A Yndestad; P Aukrust; S S Frøland
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

Review 6.  Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis.

Authors:  Anders Tveita; Ole Petter Rekvig; Svetlana N Zykova
Journal:  Arthritis Res Ther       Date:  2008-12-01       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.